Stockholm - Free Realtime Quote SEK

Egetis Therapeutics AB (publ) (EGTX.ST)

3.1900
-0.0400
(-1.24%)
As of 10:47:50 AM GMT+2. Market Open.
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
46,700
46,100
57,600
22,500
38,300
Cost of Revenue
18,600
11,600
11,000
142,600
96,600
Gross Profit
28,200
34,500
46,600
-120,100
-58,300
Operating Expense
346,200
356,300
357,900
77,000
46,800
Operating Income
-318,000
-321,800
-311,300
-197,100
-105,100
Net Non Operating Interest Income Expense
-16,100
-10,700
700
800
-100
Pretax Income
-331,100
-343,200
-326,800
-193,800
-104,500
Tax Provision
300
300
100
0
0
Net Income Common Stockholders
-331,500
-343,600
-326,900
-193,800
-104,500
Diluted NI Available to Com Stockholders
-331,500
-343,600
-326,900
-193,800
-104,500
Basic EPS
-1.00
--
-1.30
-1.00
-0.60
Diluted EPS
-1.00
--
-1.30
-1.00
-0.60
Basic Average Shares
323,204.0910
--
256,752.2820
194,238.2100
179,906.4570
Diluted Average Shares
327,095.3640
--
260,011.4780
194,238.2100
179,906.4570
Total Operating Income as Reported
-325,500
-329,400
-324,800
-198,100
-105,700
Total Expenses
364,800
367,900
368,900
219,600
143,400
Net Income from Continuing & Discontinued Operation
-331,500
-343,600
-326,900
-193,800
-104,500
Normalized Income
-336,960
-340,027
-324,756.2000
-193,800
-104,500
Interest Income
7,600
6,900
4,900
900
100
Interest Expense
23,700
17,600
4,200
100
200
Net Interest Income
-16,100
-10,700
700
800
-100
EBIT
-307,400
-325,600
-322,600
-193,700
-104,300
EBITDA
-307,400
-322,100
-319,000
-191,000
-101,800
Reconciled Cost of Revenue
18,600
11,600
11,000
142,600
96,600
Reconciled Depreciation
--
3,500
3,600
2,700
2,500
Net Income from Continuing Operation Net Minority Interest
-331,500
-343,600
-326,900
-193,800
-104,500
Total Unusual Items Excluding Goodwill
9,100
-4,500
-2,700
0
--
Total Unusual Items
9,100
-4,500
-2,700
0
--
Normalized EBITDA
-316,500
-317,600
-316,300
-191,000
-101,800
Tax Rate for Calcs
0.0004
0.0002
0.0002
0
0
Tax Effect of Unusual Items
3,640
-927
-556.2000
0
0
12/31/2021 - 4/7/2011

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HNSA.ST Hansa Biopharma AB (publ)
24.18
-0.08%
 
GUARD.ST Guard Therapeutics International AB (publ)
15.75
+4.30%
 
APTA.ST Aptahem AB (publ)
1.0000
-13.79%
 
ALNFL.PA NFL Biosciences SA
1.5560
+2.42%
 
BIOA-B.ST BioArctic AB (publ)
194.00
+4.86%
 
ALVAL.PA Valbiotis SA
1.0800
+1.12%
 
XSPRAY.ST Xspray Pharma AB (publ)
30.90
+1.98%
 
IVACC.ST Intervacc AB (publ)
1.1560
-1.03%
 
XBRANE.ST Xbrane Biopharma AB (publ)
0.2526
-4.32%
 
INIT.ST Initiator Pharma A/S
3.7000
-0.27%